Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Resource Type
Authors
Hopcroft L; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Wigmore EM; Early Data Science, Oncology Data Science, AstraZeneca, Cambridge, UK.; Williamson SC; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Ros S; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Eberlein C; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Moss JI; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Urosevic J; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Carnevalli LS; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Talbot S; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Bradshaw L; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Blaker C; Bioscience Early Oncology, AstraZeneca, Cambridge, UK.; Gunda S; Information Technology, AstraZeneca, Chennai, Tamil Nadu, India.; Owenson V; Imaging Sciences, AstraZeneca, Cambridge, UK.; Hoffmann S; Imaging Sciences, AstraZeneca, Cambridge, UK.; Sutton D; Imaging Sciences, AstraZeneca, Cambridge, UK.; Jones S; Imaging Sciences, AstraZeneca, Cambridge, UK.; Goodwin RJA; Imaging Sciences, AstraZeneca, Cambridge, UK.; Willis BS; Bioscience Early Oncology, AstraZeneca, Boston, MA, USA.; Rooney C; Translational Medicine, AstraZeneca, Cambridge, UK.; de Bruin EC; Translational Medicine, AstraZeneca, Cambridge, UK.; Barry ST; Bioscience Early Oncology, AstraZeneca, Cambridge, UK. Simon.T.Barry@astrazeneca.com.
Source
Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE